[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603745":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":25,"id":57,"slug":25,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":81,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Thammasat University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dinalbuphine Sebacate","EXPERIMENTAL","Naldebain 150mg\u002F2mL IM",[13],"Drug: Dinalbuphine Sebacate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Normal saline 2 mL IM",[19],"Drug: Normal Saline",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Normal Saline","Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Supakit Kanitnate, M.D.","CONTACT","+66 899853635","naypeng@hotmail.com",[37],{"facility":5,"status":25,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Khlong Luang","Changwat Pathum Thani","12120","Thailand",{"type":43,"coordinates":44},"Point",[45,46],100.64578,14.06467,{"lat":46,"lon":45},[49,51],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":50},"naypenf@hotmail.com",{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Nattapol Tammachote, M.D.","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Supakit Kanitnate","Principal investigator","100603745",false,"NCT07140510","Dinalbuphine Sebacate in Postoperative Pain Control After TKA","Effectiveness of Dinalbuphine Sebacate in Postoperative Pain Control Following Total Knee Arthroplasty: A Randomized Double Blinded Placebo-controlled Trial","Naldebain","Inclusion Criteria:\n\n* Osteoarthritic knee patients underwent unilateral primary TKA\n* Age 50-90 years\n* ASA class I-III\n* Participants understand and consent to the protocol of the trial\n\nExclusion Criteria:\n\n* Morbid obesity (BMI\\>40)\n* Knee osteoarthritis from inflammatory knee arthritis, trauma, infection\n* Previous knee surgery\n* Cognitive disorder\n* Liver disease\n* Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate\n* CYP3A4 inhibitor and inducer drugs used","ALL","50 Years","90 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty",[75,76],"Osteo Arthritis of the Knee","Total Knee Anthroplasty",[9,62,78,79,80],"Subacute pain","postoperative pain","total knee arthroplasty","NOT_YET_RECRUITING","2025-08-18",{"date":84,"type":85},"2025-08-24","ACTUAL",{"date":87,"type":69},"2025-10",{"date":89,"type":69},"2026-09",{"name":5,"class":6},1]